Industry Wire 198

August 2, 2024 Jake Fishman 0 min read
  1. Jefferson and Lehigh Valley Health complete $15B mega-merger.
  2. WaPo profiles ‘one-stop’ hospitals with ERs and urgent care.
  3. Ransomware attack on large blood donation network.
  4. MyMichigan Health acquires Ascension’s Northern Michigan hospitals. 
  5. Cigna may soon become out-of-network at Dignity Health.
  6. NC to give hospitals extra Medicaid funds for forgiving medical debt.
  7. UAB Medical West opens new $400M hospital.
  8. Testimony: computer error wrongly stripped Florida Medicaid coverage.
  9. Average healthcare data breach cost $10M in 2024.
  10. Less than half of patients challenge medical billing errors.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Surgeries & Interventions February 19, 2026

Evolut Low Risk, A Tale of Two Outcomes February 19, 2026

We might need to reconsider the concept of a TAVR-first strategy for low-risk aortic stenosis patients, after extended results from the Evolut Low Risk trial showed that reintervention rates at seven years were considerably higher in TAVR recipients compared to surgical replacement. As has been the case for each yearly follow-up, the trial examined 1.4k […]

Heart Failure February 19, 2026

Rethinking Hyperkalemia Care in Patients With Heart Failure February 19, 2026

By Ravi Dhingra, MD, MPH, FACC, FAHASponsored By AstraZeneca Renin-angiotensin-aldosterone system inhibitor (RAASi) therapy is a cornerstone of heart failure (HF) management, yet concerns about hyperkalemia (HK) can limit its use.1 In chronic HF management, a long-term approach to addressing HK is an important consideration for healthcare providers. An observational study2 utilizing Optum’s de-identified Market Clarity Data […]

Cardiology Pharmaceuticals February 16, 2026

DAPT Drugs Matter to Diabetics with Multivessel CAD February 16, 2026

The debate over which dual antiplatelet therapy is best for diabetic CAD patients might favor generic prasugrel over ticagrelor (AstraZeneca’s Brilinta), after the TUXEDO-2 trial demonstrated that ticagrelor isn’t equivalent to prasugrel in this complex patient group. The TUXEDO-2 trial enrolled 1.8k participants across 66 clinical sites in India and randomized patients undergoing PCI to […]